Author: Malone, Robert W.; Tisdall, Philip; Fremont-Smith, Philip; Liu, Yongfeng; Huang, Xi-Ping; White, Kris M.; Miorin, Lisa; Olmo, Elena Moreno Del; Alon, Assaf; Delaforge, Elise; Hennecker, Christopher D.; Wang, Guanyu; Pottel, Joshua; Bona, Robert; Smith, Nora; Hall, Julie M.; Shapiro, Gideon; Clark, Howard; Mittermaier, Anthony; Kruse, Andrew C.; GarcÃa-Sastre, Adolfo; Roth, Bryan L.; Glasspool-Malone, Jill; Francone, Victor; Hertzog, Norbert; Fremont-Smith, Maurice; Ricke, Darrell O.
Title: COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms Cord-id: fod0eyuj Document date: 2020_6_22
ID: fod0eyuj
Snippet: SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We explore several plausible avenues of activity including antiviral and host-mediated actions. We propose that the principal famoti
Document: SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. Currently, there are no pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure. We explore several plausible avenues of activity including antiviral and host-mediated actions. We propose that the principal famotidine mechanism of action for COVID-19 involves on-target histamine receptor H (2) activity, and that development of clinical COVID-19 involves dysfunctional mast cell activation and histamine release.
Search related documents:
Co phrase search for related documents- abnormal coagulation and acute myocardial infarction: 1
- abnormal coagulation and acute phase: 1, 2
- abnormal coagulation and lymphocyte count: 1, 2
- absorption pharmacokinetic and acute ards respiratory distress syndrome: 1
- absorption pharmacokinetic and adaptive immune response: 1
- absorption pharmacokinetic and adenosine monophosphate: 1
- absorption pharmacokinetic and low energy: 1
Co phrase search for related documents, hyperlinks ordered by date